Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Angus

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Biorxiv : the Preprint Server for Biology|December 25, 2025
Genetic activation of ERK2 recapitulates core neurodevelopmental features of Rasopathy syndromes in miceKassidy E Grover, Zoe R Cappel, Avery Volz, et al.
European Journal of Human Genetics : EJHG|March 12, 2015
Redefining the MED13L syndromeAbidemi Adegbola, Luciana Musante, Bert Callewaert, et al.
Immunity|September 26, 2025
Intra-tumoral hypoxia promotes CD8<sup>+</sup> T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4Coral Del Mar Alicea Pauneto, Brian P Riesenberg, Evelyn J Gandy, et al.
NPJ Breast Cancer|May 13, 2021
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036Steven P Angus, Timothy J Stuhlmiller, Gaurav Mehta, et al.
Nature Medicine|January 14, 2021
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trialMichael J Fisher, Chie-Schin Shih, Steven D Rhodes, et al.
Neoplasia (New York, N.Y.)|January 16, 2026
Dual CDK4/6-PI3K/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcomaFarinaz Barghi, M Reza Saadatzadeh, Erika A Dobrota, et al.
Nature Medicine|January 6, 2025
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trialAndrea M Gross, Geraldine O'Sullivan Coyne, Eva Dombi, et al.
Journal of Medicinal Chemistry|April 30, 2026
Optimization and Characterization of SHIP1 Ligands for Cellular Target Engagement and Activity in Alzheimer's Disease ModelsCynthia D Jesudason, Claudia Rangel-Barajas, Colin J Beach, et al.
Biorxiv : the Preprint Server for Biology|January 9, 2026
Optimization and Characterization of SHIP1 Ligands for Cellular Target Engagement and Activity in Alzheimer's Disease ModelsCynthia D Jesudason, Claudia Rangel-Barajas, Colin J Beach, et al.
Plos One|July 15, 2021
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALKLong-Sheng Chang, Janet L Oblinger, Abbi E Smith, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Biorxiv : the Preprint Server for Biology|December 25, 2025
Genetic activation of ERK2 recapitulates core neurodevelopmental features of Rasopathy syndromes in miceKassidy E Grover, Zoe R Cappel, Avery Volz, et al.
European Journal of Human Genetics : EJHG|March 12, 2015
Redefining the MED13L syndromeAbidemi Adegbola, Luciana Musante, Bert Callewaert, et al.
Immunity|September 26, 2025
Intra-tumoral hypoxia promotes CD8<sup>+</sup> T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4Coral Del Mar Alicea Pauneto, Brian P Riesenberg, Evelyn J Gandy, et al.
NPJ Breast Cancer|May 13, 2021
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036Steven P Angus, Timothy J Stuhlmiller, Gaurav Mehta, et al.
Nature Medicine|January 14, 2021
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trialMichael J Fisher, Chie-Schin Shih, Steven D Rhodes, et al.
Neoplasia (New York, N.Y.)|January 16, 2026
Dual CDK4/6-PI3K/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcomaFarinaz Barghi, M Reza Saadatzadeh, Erika A Dobrota, et al.
Nature Medicine|January 6, 2025
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trialAndrea M Gross, Geraldine O'Sullivan Coyne, Eva Dombi, et al.
Journal of Medicinal Chemistry|April 30, 2026
Optimization and Characterization of SHIP1 Ligands for Cellular Target Engagement and Activity in Alzheimer's Disease ModelsCynthia D Jesudason, Claudia Rangel-Barajas, Colin J Beach, et al.
Biorxiv : the Preprint Server for Biology|January 9, 2026
Optimization and Characterization of SHIP1 Ligands for Cellular Target Engagement and Activity in Alzheimer's Disease ModelsCynthia D Jesudason, Claudia Rangel-Barajas, Colin J Beach, et al.
Plos One|July 15, 2021
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALKLong-Sheng Chang, Janet L Oblinger, Abbi E Smith, et al.
Pageof 6